Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;329:460-461 (21 August), doi:10.1136/bmj.329.7463.460-c
| The first 150 words of the full text of this article appear below. |
EDITORMatheson says that it is misleading for Herxheimer in his open letter to New Zealand's health minister to report that Medsafe, the New Zealand medicines regulator, intended to stop funding the intensive medicines monitoring programme (previous letter).1 2 Notice was given to the University of Otago on 4 March 2004 that funding would be withdrawn as of 30 June. Medsafe's intention was demonstrated further by the withdrawal of all usual references to the programme from the latest issue of their publication Prescriber Update, and from their web site. It is Matheson's letter that is misleading.
Matheson is also critical of the fact that the collection of data comes from multiple sources and is largely paper-based. He overlooks the fact that the programme has no operational alternative because of failure of Medsafe or the ministry to have prescriptions for monitored medicines recorded by a central agency. This is in
David Coulter, retired
264 Highgate, Roslyn, Dunedin 9001, New Zealand dmcoulter@xtra.co.nz